Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Gospodarevskaya E, Picot J, Cooper K, Loveman E, Takeda A. Ustekinumab for the treatment of moderate to severe psoriasis. Health Technology Assessment 2009; 13(Suppl 3 Article 10) Indexing Status Subject indexing assigned by NLM MeSH Adult; Antibodies, Monoclonal /adverse effects /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Cost-Benefit Analysis; Dermatologic Agents /adverse effects /economics /therapeutic uses; Psoriasis /drug therapy /economics; Randomized Controlled Trials as Topic; Ustekinumab Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32013000638 Date abstract record published 19/08/2013 |